Indications -- Asthma/Allergy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Asthma/Allergy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (43)	5/14/2003 11:12:20 AM
From: scaram(o)uche	of 86

Xolair shown to benefit some asthma patients--FDA Wednesday May 14, 11:05 am ET NEW YORK, May 14 (Reuters) - Xolair, an experimental drug from Genentech Inc. (NYSE:DNA - News) and Novartis AG (NOVZn.VX), met its goal of preventing some asthma patients from developing worse symptoms, staff members of the U.S. Food and Drug Administration (News - Websites) said in a report. The FDA report, placed on the FDA's Web site in preparation for a meeting on Thursday to review the injectable medicine, said Xolair was associated with a "reduction in the exacerbations" in patients who were also taking moderate to high doses of a popular class of asthma drugs called inhaled corticosteroids. Although the clinical trials were successful, the report said the magnitude of benefit to patients "in absolute terms was small, and was seen in a minority of subjects in the trials."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next